|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In contrast, Ttzm, whose therapeutic activity also depends on its binding to the extracellular domain of HER2, cannot perform any of these functions of PEPD<sup>G278D</sup> PEPD<sup>G278D</sup> inhibits HER2-BC cells and tumors that carry clinically relevant molecular changes that confer resistance to Ttzm.
|
30674653 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women.
|
24667716 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The presently reported immunoliposomal delivery system was successfully used in vivo to inhibit HER-2 expression, and thus induce apoptosis in human breast carcinoma tumors (MDA-MB-435) in mice upon repeated i.v. treatment at a dose of 3 mg/kg of H or mH.
|
16901821 |
2006 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
This study was conducted to evaluate the quantitative assessment of HER2/neu expression by enzyme immunoassay (EIA) and its prognostic significance in differentiating between high and low proliferating tumors.
|
15642276 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The pathway activation patterns were segregated based on the tumor HER2 status.
|
23372746 |
2013 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Tumors were required to have HER2 overexpression (2+ or 3+ immunohistochemical staining) or HER2 amplification (FISH HER2/CEP 17 ratio >2.0).
|
19840887 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
We previously created a recombinant replicating vesicular stomatitis virus (VSV) that preferentially infected Her2/neu expressing breast cancer cells and showed therapeutic efficacy in an implanted Balb/c mouse tumor model.
|
22240921 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This prospective study confirms that high c-erbB-2 protein values are linked to poor prognostic factors and shows for the first time that low values are also linked to hormone receptor negative tumours, suggesting that these low values might also have a negative prognostic significance.
|
9713296 |
1998 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The basal-like and erbB2+ subgroups were associated with the highest rates of pathologic complete response (CR), 45% [95% confidence interval (95% CI), 24-68] and 45% (95% CI, 23-68), respectively, whereas the luminal tumors had a pathologic CR rate of 6% (95% CI, 1-21).
|
16115903 |
2005 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Both groups had similar mean age, mean tumor (invasive and ductal carcinoma-in-situ) size, histologic grade distribution, presence of lymphovascular invasion, and extensive intraductal component, nodal status, and hormone receptor and HER2 status.
|
30718114 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Identifying risk factors for less common subtypes such as luminal B, HER2-type and basal-like tumors has important implications for prevention of these more aggressive subtypes.
|
21830014 |
2012 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Significantly, no cytocidal effect was observed in non-erbB-2-overexpressing tumors.
|
8729907 |
1996 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
A total of 618 newly diagnosed BC patients were identified from a cancer registry within a single institution with standardized methods of tumor assessment for estrogen receptor (ER), progesterone receptor (PR), and HER-2.
|
20814819 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Over the past few years, anti-HER2 targeted therapies have proven to be a key treatment in the management of human epidermal growth receptor 2 (HER2)-positive breast cancers, as well as gastrointestinal tract tumors and head and neck tumors.
|
28751231 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.
|
28459074 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.
|
18292797 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The immunotoxin has shown pronounced antitumor effect on cancer cells overexpressing HER2 receptor in vitro and on HER2-positive experimental tumors in vivo.
|
28423549 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This chapter outlines materials and methods for the: (1) production of HER-2 targeted nanoparticles; (2) establishment of an orthotopic human ovarian cancer xenograft model; (3) monitoring of tumor growth by bioluminescence imaging; (4) administration of targeted nanoparticles followed by NIR optical imaging for the detection of orthotopic ovarian cancers with targeted accumulation of the nanoparticle imaging probes.
|
25308269 |
2015 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In in vivo experiment, we confirmed how DOC enhanced the recruitment of HER2-CAR T cells to tumor sites.
|
30744691 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In a limited number of cases (18 gliomas and two meningiomas) of the tumor series tested other mAbs against neu/c-erbB-2 epitopes, especially the mabs 9G6 and CB11, gave qualitatively comparable results.
|
7914508 |
1994 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results were validated in vivo in HER2-amplified patient derived tumor xenografts from three metastatic colorectal cancer patients.
|
31164152 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Normal-like tumors resemble normal breast tissue and the HER2 subtype is characterized by HER2 overexpression.
|
22202065 |
2012 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Additionally, MET and HER2 overexpression were found in patient tumors, PDXs, and PDX cells.
|
28806950 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
We conclude that a single lymph node library of moderate diversity (2 x 10(7) kappa light chain and gamma heavy chain clones), when derived from an individual whose colorectal tumour over-expressed c-erbB-2, can be successfully panned to isolate a number of unique Fabs specific for this antigen.
|
9218840 |
1997 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Humoral and cellular responses raised against the human HER2 oncoprotein are cross-reactive with the homologous product of the new proto-oncogene, but do not protect rats against B104 tumors expressing mutated neu.
|
8640846 |
1996 |